Palivizumab

DB00110ApprovedInvestigationalProtein Based TherapiesRespiratory Syncytial Virus Anti-F Protein Monoclonal Antibody

Palivizumab is a monoclonal anti respiratory syncytial virus F protein antibody used to prevent serious sequelae caused by respiratory syncytial virus infection in pediatric patients. Humanized monoclonal antibody (IgG1k) produced by recombinant DNA technology, directed to an epitope in the A antigenic site of the F protein of respiratory syncytial virus (RSV).

Protein structure of Palivizumab
Mechanism
Curator reviewed
Primary indication
For prophylaxis of respiratory diseases casued by respiratory syncytial virus.Curator reviewed · 3 structured indications
First approval
Canada, 2012 · United States, 1998 · European Union, 2016
Code names
MEDI 493
Brand names
  • Synagis

Resolves to

Compound
UNIIDQ448MW7KSCAS188039-54-5ChEMBLCHEMBL1201586
Clinical / RWD
RxNorm194279ATCJ06BD01PharmGKBPA164748781
Targets
P13843FO75015FCGR3BP08637FCGR3AP12314FCGR1AP00736C1RP02745C1QAP02746C1QBP02747C1QC+2 more

What you can answer from here — as of July 17, 2026

10Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
396Drug interactionsStructured to mechanism, not free text
Sign in
15Clinical trialsPhase, status and sponsor resolved per trial
Sign in
3Structured indicationsCondition, population, route and combination as fields, not prose
Sign in
31Marketed productsAcross 8 countries and 7 labellers
Sign in
1ATC codeIncluding every combination product, plus 18 drug categories
Sign in
12+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Palivizumab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In